Companies have agreed to develop a sterile eye drop dosage formulation, based on a cannabinoid, for Glaucoma
Nemus Bioscience has signed an agreement with Pharmaceuticals International, a CDMO, to develop a sterile eye drop dosage formulation of NB1111 for human dosing.
The California-based biopharmaceutical company is focused on bioengineering cannabinoid-based therapeutics to address global medical indications. NB1111 is its proprietary prodrug of tetrahydrocannabinol (THC) that is currently undergoing development for the treatment of glaucoma.
Commenting on the announcement, Brian Murphy, CEO and Chief Medical Officer of Nemus, said: “Pharmaceuticals International is an experienced formulator of ocular-based therapies and we look forward to working with them, and our discovery and research colleagues at the University of Mississippi, to advance a clinical-grade formulation of NB1111 into the clinic.”
The collaboration aims to conduct a first-in-human, single-ascending dose clinical trial in Australia on patients with mild to moderate glaucoma.
Dr Kurt Nielsen, Pharmaceuticals International’s President and CEO, added: “We look forward to partnering with Nemus to develop an ophthalmic formulation of NB1111 as an improved treatment option for patients with glaucoma.”
For Nielsen, the CDMO’s product development knowledge will be a key contributor to ensuring on-time delivery of the NB1111 formulation for evaluation in the planned clinical trial.